In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic: Doing Just What the Doctors Order

Executive Summary

Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.

You may also be interested in...



Leaving Medtronic: Bill Hawkins' Legacy

An interview with retiring Medtronic CEO Bill Hawkins.

AF Ablation: Finding the Right Mix

For a number of reasons, 2009 was a big year for the atrial fibrillation ablation market. Early in the year, Biosense Webster received FDA approval for its radiofrequency ablation catheter, the first such device to launch in the US with a specific AF indication. That approval was much more than just a landmark event for J&J; it changed the landscape of the AF industry, reinvigorating interest in the funding and development of new catheter-based technologies--a trend that has extended through to 2010 and will likely continue in the years ahead.

Remembering Donald Baim

Among the most extraordinary developments both in clinical medicine and in the medical device industry over the past 30 years has been the birth and growth of interventional cardiology. IN VIVO remembers Donald Baim, one of the pioneers of the field, who died on November 6, 2009 at the age of 60.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel